We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » India Clarifies Clinical Trial Requirements for Biosimilar Makers
India Clarifies Clinical Trial Requirements for Biosimilar Makers
To provide a more unified approach in evaluating biosimilars, India’s Central Drugs Standard Control Organization is requiring sponsors to conduct equivalence, non-inferiority or comparability Phase 3 clinical trials.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor